Current Price | $6.10 | Mkt Cap | $158.6M |
---|---|---|---|
Open | $6.01 | P/E Ratio | -1.62 |
Prev. Close | $6.10 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $5.99 - $6.23 | Volume | 149,981 |
52-Wk Range | $2.09 - $8.17 | Avg. Daily Vol. | 234,304 |
Current Price | $6.10 | Mkt Cap | $158.6M |
---|---|---|---|
Open | $6.01 | P/E Ratio | -1.62 |
Prev. Close | $6.10 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $5.99 - $6.23 | Volume | 149,981 |
52-Wk Range | $2.09 - $8.17 | Avg. Daily Vol. | 234,304 |
The best Bull and Bear pitches based on recency and number of recommendations.
There are no pitches that meet the Top Bull criteria. Explain
If this upsets you, start recommending pitches below!
I miss those two years in the nineties when instead of using sarcasm we’d just say the opposite of what we were thinking followed by “NOT”
Read the most recent pitches from players about SYRS.
Recs
Potential big winner in treating blood cancers like acute myeloid leukemia (AML). The company is on track to report Phase 2 data from its AML program later this year.
Good results could send SYRS shares soaring.
In the meantime, however, the GBT partnership news is sending SYRS shares up sharply over the past month.
Syros’ therapies, like its AML drug called SY-1425, work by controlling how genes are expressed. In cancer, this could be a very valuable approach, since shutting down cancer genes could help create new treatments.
But Syros’ gene expression platform could be broadly applicable to other types of disease including sickle cell disease and beta thalassemia.
Global Blood Therapeutics wants to tap into Syros’ drug discovery engine to find new targets and leads, with a primary interest in finding a way to induce the production of fetal hemoglobin through an oral drug.
Success means GBT will gain exclusive license to develop these leads into commercial therapies, potentially producing a functional cure. For Syros, success is a $20 million upfront payment, access to future milestone payments and three years of preclinical research payments.
Find the members with the highest scoring picks in SYRS.
chushogi (54.53) Score: +153.35
The Score Leader is the player with the highest score across all their picks in SYRS.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
Under5 | 62.19 | 12/7/2023 | 5Y | $4.00 | +52.50% | +12.25% | +40.25 | 0 Comment | ||
Under5b | < 20 | 2/27/2024 | 5Y | $7.57 | -19.42% | +0.90% | +20.32 | 0 Comment | ||
JimAnder | 67.04 | 9/19/2022 | 5Y | $5.27 | +15.75% | +34.17% | -18.42 | 0 Comment | ||
mdriver78 | 64.93 | 1/24/2020 | 5Y | $7.66 | -20.37% | +54.81% | -75.18 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.